If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The strategic mission of the SSM-N-8 and the P-5 was taken up by submarine-launched ballistic missile beginning with the US Navy's Polaris missile, and subsequently the Poseidon and Trident missiles. Germany is working on the torpedo tube-launched short-range IDAS missile, which can be used against ASW helicopters, as well as surface ships and coastal targets.
=== Xen Museum === The Crowbar Collective released an expansion in April 2021 called Xen Museum that presents a virtual museum that documents the team's past five years of effort in creating Black Mesa and mostly their work in recreating Xen from the original Half-Life.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy, or molly) is an entactogen, euphoriant, and psychostimulant of the amphetamine class. Briefly used by some psychotherapists as an adjunct to therapy, the drug became popular recreationally and, in the United States, the DEA listed MDMA as a Schedule I controlled substance, prohibiting most medical studies and applications. MDMA is known for its entactogenic properties. The stimulant effects of MDMA include hypertension, anorexia (appetite loss), euphoria, social disinhibition, insomnia (enhanced wakefulness/inability to sleep), improved energy, increased arousal, and increased perspiration, among others. Relative to catecholaminergic transmission, MDMA enhances serotonergic transmission significantly more, when compared to similar psychostimulants like amphetamine. Due to the relative safety of MDMA, some researchers such as David Nutt have criticized the scheduling level, writing a satirical article finding MDMA to be 28 times less dangerous than horseriding, a condition he termed "equasy" or "Equine Addiction Syndrome".
Ian Buruma, author and journalist; board member of Human Rights in China; fellow of European Council of Foreign Relations; journalist for The New York Review of Books and has written for The Guardian; held fellowships at Wissenschaftskolleg and at Woodrow Wilson International Center for Scholars in Washington, D.C.; was Alistair Horne fellow of St Antony's College in Oxford. Stephen Bush; ( b. 1990) columnist and associate editor at the Financial Times; has written for The Guardian, The Daily Telegraph, The Jewish Chronicle, Jewish News, Times of Israel, The i Paper and New Statesman; runner-up in the Young Journalist of the Year awards category in Press Awards; was awarded Political Studies Association's Journalist of the Year award;was appointed to chair the Board of Deputies of British Jews' Commission on Racial Inclusivity in the Jewish Community. Barbara Charone author of authorised biography of Keith Richards; board member of Chelsea F.C.; journalist and music critic for the NME, Rolling Stone, Sounds magazine and Creem; public relations and press director at WEA; founded the agency MBC PR where clients include Madonna, Depeche Mode, Primal Scream, Robert Plant, Pearl Jam, Rod Stewart and Christina Aguilera as well as comedians David Walliams, Graham Norton and Russell Brand; won the Music Week Press Award in 2006 and 2009; The Guardian included her on list of "The 20 most powerful celebrity makers" as "Britain's most powerful music PR", citing her reviving of careers of Madonna and Neil Diamond and establishing Duffy and Mark Ronson. Charone is on Chelsea F.C.
Sources: en.wikipedia.org
A 2022 study concluded that the practice of rinsing uncooked chicken actually increases the risk of pathogen transfer through the splashing of water droplets, with factors such as faucet height, flow type, and surface stiffness affecting the risk of cross-contamination. The most common bacterial foodborne pathogens are:
In 2008, Freeman was cast in the action-thriller Wanted, a loose adaptation of the comic book miniseries by Mark Millar and J. G. Jones. The plot revolves around Wesley Gibson (James McAvoy), a frustrated account manager who discovers that he is the son of a professional assassin and decides to join the Fraternity, a secret society of which Sloan (Freeman) is the leader. Principal photography took place in Chicago; co-star rapper Common remarked on the set atmosphere: "Freeman is a cool guy. He'd be walking around joking and singing and just dancing. You know, artists are free and I just felt the freedom in him." The film received generally favorable reviews; Peter Howell of Toronto Star thought it was original and one of Freeman's bolder performances to date. Freeman narrated The Love Guru (2008), before appearing in The Dark Knight (2008), the second installment of Christopher Nolan's Dark Knight Trilogy, in which he reprised his role as Lucius Fox. Freeman returned to Broadway in 2008 after an eighteen-year absence to co-star with Frances McDormand and Peter Gallagher in Clifford Odets' play, The Country Girl, directed by Mike Nichols. Freeman continued to accept roles in a diverse range of genres. In 2009, Freeman starred opposite Antonio Banderas in the heist movie Thick as Thieves. Next, he collaborated with Christopher Walken and William H. Macy for the comedy The Maiden Heist. For some time, Freeman expressed a desire to do a film based on Nelson Mandela.
== Bibliography == R N Kaul (1963): Need for afforestation in the arid zones of India, LA-YAARAN, Vol 13 R C Ghosh (1977): Hand book on afforestation techniques, Dehradun. R K Gupta & Ishwar Prakasah (1975): Environmental analysis of the Thar Desert, Dehradun.
Sources: en.wikipedia.org
=== Non-diabetics === In those with hypoglycemia who do not have diabetes, there are a number of preventative measures dependent on the cause. Hypoglycemia caused by hormonal dysfunction like lack of cortisol in Addison's disease or lack of growth hormone in hypopituitarism can be prevented with appropriate hormone replacement. The hypoglycemic episodes associated with non-B cell tumors can be decreased following surgical removal of the tumor, as well as following radiotherapy or chemotherapy to reduce the size of the tumor. In some cases, those with non-B cell tumors may have hormone therapy with growth hormone, glucocorticoid, or octreotide to also lessen hypoglycemic episodes. Post-gastric bypass hypoglycemia can be prevented by eating smaller, more frequent meals, avoiding sugar-filled foods, as well as medical treatment with an alpha-glucosidase inhibitor, diazoxide, or octreotide. Some causes of hypoglycemia require treatment of the underlying cause to best prevent hypoglycemia. This is the case for insulinomas which often require surgical removal of the tumor for hypoglycemia to remit. In patients who cannot undergo surgery for removal of the insulinoma, diazoxide or octreotide may be used.
== Season 6 (2020) == Season 6 is themed around a haunted house. Carla Hall acts as both a judge and the host, leading the contestants on a tour of a different themed room in each episode. Unlike other seasons, the first six episodes of this season each contained only one challenge.
Medical staff at remote hospitals and clinics place orders with Zipline, a fulfillment operator receives this order and prepares the medical products into a special delivery package with a parachute. A Zipline flight operator then packs the medical products into a drone and performs pre-flight checks. The drone is then launched with a supercapacitor-powered electric catapult launcher which accelerates it to 67 miles per hour (108 km/h) in 0.33 seconds. The drone cruises at 101 km/h (63 mph) at an altitude of 80–120 metres (260–390 ft) above ground level, while a remote pilot at each distribution center monitors all drones in flight. The drone descends to 20–35 metres (66–115 ft) before dropping the package under a paper "Drogue" parachute. A payload can land within a 5 m (16 ft) diameter landing zone. The drone then returns to the distribution center and lands by its tail hook catching an arresting gear, similar to airplanes landing on an aircraft carrier. A Zipline distribution center can deliver medical supplies reliably anywhere within 100 km (62 mi), even accounting for mountainous terrain and severe weather.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.